Liquidia Corporation (NASDAQ: LQDA) announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. The biopharmaceutical company, which focuses on respiratory and vascular diseases, will host a live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a broader corporate update. This disclosure sets the timeline for investors to assess the company’s operational and financial performance for the period ending June 30, 2026.

The webcast will be streamed live on Liquidia’s investor relations page at https://liquidia.com/investors/events-and-presentations . Following the live event, a rebroadcast of the presentation will be archived at the same location for a period of one year, ensuring continued access for stakeholders who cannot attend the initial broadcast.

Corporate Overview

Liquidia Corporation operates as a biopharmaceutical entity driven by science to revolutionize care for patients with challenging respiratory and vascular diseases. The company leverages its proprietary PRINT™ technology to develop precise, innovative therapies. Key products in its portfolio include YUTREPIA™ (treprostinil) inhalation powder, which is approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

In addition to its marketed therapies, Liquidia is actively developing L606, an investigational extended-release formulation of treprostinil administered twice daily using a next-generation nebulizer. The company also currently markets generic Treprostinil Injection for the treatment of PAH, maintaining a diversified approach within the pulmonary hypertension therapeutic area.

Investor and Media Contacts

For inquiries regarding the financial results and investor relations matters, Jason Adair, Chief Business Officer, is the designated contact point. He can be reached at 919.328.4350 or via email at jason.adair@liquidia.com . Media-related questions should be directed to media@liquidia.com .

What the Numbers Show

While specific financial metrics for Q2FY26 are not yet disclosed, the announcement confirms the company’s adherence to standard reporting cycles. The upcoming webcast will likely detail revenue trends from YUTREPIA™ and generic Treprostinil Injection, as well as progress on the development of L606. Investors should monitor the August 12 presentation for updates on clinical trials, regulatory milestones, and cash position, which are critical indicators for biopharmaceutical firms in the growth phase.

Liquidia Corporation reported its third consecutive quarter of profitability for the first quarter of 2026, fueled by strong demand for its Eutrepia product. The company achieved a half-billion-dollar annualized revenue run rate less than a year after launch, with management targeting at least $1 billion in net revenue by 2027. Liquidia is funding its growth initiatives, including clinical studies and manufacturing expansion, entirely through operating cash flow.

Financial Performance

Net product sales for Eutrepia reached $129.9 million in the first quarter of 2026, up from $90.1 million in the fourth quarter of 2025. This represents a 44% sequential growth in net product sales. The company reported net income of approximately $52.9 million, an increase from $14.6 million in the prior quarter. Non-GAAP adjusted EBITDA was approximately $71.2 million, up from $27.3 million in the fourth quarter of 2025.

Liquidia ended the quarter with approximately $222.8 million in cash and cash equivalents, an increase of $32.1 million from year end. The company recorded income tax expense in the first quarter and expects to continue paying taxes as profitability grows.

Commercial and Operational Updates

As of April 30, Liquidia received approximately 4,500 unique patient prescriptions and started approximately 3,750 patients on therapy since launch. Approximately 980 physicians have prescribed Eutrepia. The number of physicians prescribing to five or more patients grew 25% since the end of February to approximately 270.

Management noted that Eutrepia is leading the growth of the inhaled prostacycline category. The company is expanding its sales force to drive awareness in the PH-ILD and community pulmonologist sectors. Liquidia is also building new manufacturing capacity in North Carolina.

Clinical Development

Liquidia is advancing several clinical programs to expand its portfolio. The company has started recruiting for Cohort B of the ASCENT study to transition inadequate responders from Tyvaso DPI to Eutrepia. It is actively screening patients for the pivotal phase 3 RESPire study of L606, a twice-daily inhaled treprostinil suspension.

Additional clinical programs are exploring new indications for inhaled prostacyclines, including IPF, PPF, PH-COPD, and scleroderma-associated Raynaud's phenomenon. Management believes these opportunities could significantly grow the franchise value.